AXS-07 (meloxicam-rizatriptan) for Migraine

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Clinical Research Site, Charleston, SC
Migraine+1 More
AXS-07 (meloxicam-rizatriptan) - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.

Eligible Conditions

  • Migraine

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Hour 2 following dose administration

Hour 2
Percentage of subjects with absence of the Most Bothersome Symptom
Percentage of subjects with headache pain relief

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

AXS-07 (meloxicam-rizatriptan)
1 of 1
Experimental Treatment

100 Total Participants · 1 Treatment Group

Primary Treatment: AXS-07 (meloxicam-rizatriptan) · No Placebo Group · Phase 3

AXS-07 (meloxicam-rizatriptan)
Drug
Experimental Group · 1 Intervention: AXS-07 (meloxicam-rizatriptan) · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: hour 2 following dose administration
Closest Location: Clinical Research Site · Charleston, SC
Photo of Charleston 1Photo of Charleston 2Photo of Charleston 3
2005First Recorded Clinical Trial
4 TrialsResearching Migraine
19 CompletedClinical Trials

Who is running the clinical trial?

Axsome Therapeutics, Inc.Lead Sponsor
23 Previous Clinical Trials
7,067 Total Patients Enrolled
3 Trials studying Migraine
2,602 Patients Enrolled for Migraine

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have experienced an inadequate response to oral CGRP inhibitors for the acute treatment of migraine.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.